Immunogenic cell death inducers for cancer therapy: an emerging focus on natural products
LL Zhang, DJ Zhang, JX Shi, MY Huang, JM Yu… - Phytomedicine, 2024 - Elsevier
Background Immunogenic cell death (ICD) is a specific form of regulated cell death induced
by a variety of stressors. During ICD, the dying cancer cells release damage-associated …
by a variety of stressors. During ICD, the dying cancer cells release damage-associated …
Understanding the Role of Connexins in Hepatocellular Carcinoma: Molecular and Prognostic Implications
SP Papadakos, E Chatzikalil, K Arvanitakis… - Cancers, 2024 - mdpi.com
Simple Summary Hepatocellular carcinoma represents the majority of all liver cancers and
the fourth cause of cancer-related deaths worldwide. Despite the progress in diagnostic and …
the fourth cause of cancer-related deaths worldwide. Despite the progress in diagnostic and …
[HTML][HTML] A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death
J Mannion, V Gifford, B Bellenie, W Fernando… - Immunity, 2024 - cell.com
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) functions as a critical stress
sentinel that coordinates cell survival, inflammation, and immunogenic cell death (ICD) …
sentinel that coordinates cell survival, inflammation, and immunogenic cell death (ICD) …
Immunogenic oncolysis by tigilanol tiglate
Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent
study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell …
study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell …
Exploring the interplay between triple‐negative breast cancer stem cells and tumor microenvironment for effective therapeutic strategies
Z Zou, T Luo, X Wang, B Wang… - Journal of Cellular …, 2024 - Wiley Online Library
Triple‐negative breast cancer (TNBC) is a highly aggressive and metastatic malignancy with
poor treatment outcomes. The interaction between the tumor microenvironment (TME) and …
poor treatment outcomes. The interaction between the tumor microenvironment (TME) and …
Epigenetic priming by hypomethylation enhances the immunogenic potential of tolinapant in T-cell lymphoma
GA Ward, Z Zhang, S Jueliger, IS Potapov… - Cancer Research …, 2024 - AACR
Programmed cell death mechanisms are important for the regulation of tumor development
and progression. Evasion of and resistance to apoptosis are significant factors in …
and progression. Evasion of and resistance to apoptosis are significant factors in …
4-Deoxy-ϵ-Pyrromycinone: A Promising Drug/Lead Compound to Treat Tumors
J Zhang, X Sang, Y Yuan, J Shen, Y Fang… - Drug Design …, 2024 - dovepress.com
Background: Anthraquinone drugs are widely used in the treatment of tumors. However,
multidrug resistance and severe cardiac toxicity limit its use, which have led to the discovery …
multidrug resistance and severe cardiac toxicity limit its use, which have led to the discovery …